Executives from Sun Pharmaceuticals and Organon & Co. in a high-stakes meeting.
Sun Pharma is advancing towards a $12 billion bid for Organon & Co., potentially marking the largest overseas pharmaceutical acquisition by an Indian company. The deal underscores Sun Pharma’s strategic ambition to bolster its presence in innovative drug research, particularly within the women’s health sector, where Organon specializes.
The company is reportedly finalizing financing arrangements to support the substantial offer. However, Sun Pharma may face competition from other global consortiums also vying for Organon, setting the stage for a competitive acquisition process.
This move signifies a notable shift in Sun Pharma’s growth strategy, emphasizing expansion through strategic acquisitions to enhance its research and development capabilities and market reach in specialized therapeutic areas.
About the Author
